Hypera (HYPE3.SA) Akcie Kurz
Hypera Kurz
Za posledních 19 let vzrostly tržby Hypera o 17,2 % ročně a dosáhly 7,70 Mld. BRL. Zisk na akcii rostl o 15,8 % ročně za posledních 18 let. U Hypera je čistá marže 15,5 % dolů oproti 22,4 % před několika lety. Při dnešní ceně vychází dividendový výnos zhruba na 4,42 %. Výplatní poměr je kolem 63 % zisku. Dividenda rostla o 17,6 % ročně za posledních 14 let. Konsenzuální 12měsíční cílová cena pro Hypera je 30,09 BRL, asi nad cenu o 13,6 %. Z 19 analytiků jich 13 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Hypera
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Hypera a analýza akcií
Nejčastější otázky týkající se akcie Hypera
Hypera SA, a leading pharmaceutical company based in Brazil, operates on a robust business model. The core of their business involves the manufacturing, marketing, and distribution of a wide range of pharmaceutical products. Hypera SA specializes in both prescription and over-the-counter medications, catering to various therapeutic areas. They also produce medical-hospital products and non-pharmaceutical items such as personal hygiene and beauty care products. With a focus on innovation and quality, Hypera SA aims to improve the health and well-being of individuals across the country. As a prominent player in the pharmaceutical industry, Hypera SA continues to expand its product portfolio, enhance operational efficiency, and ensure customer satisfaction.
Hypera SA is primarily active in the pharmaceutical industry.
The main competitors of Hypera SA in the market are pharmaceutical companies such as Aché Laboratórios, EMS Pharma, and Eurofarma.
Hypera SA, formerly known as Hypermarcas SA, is a leading pharmaceutical company based in Brazil. Founded in 2001, Hypera has a rich history and has significantly grown over the years. It focuses on the development, production, and commercialization of pharmaceutical products, generic drugs, over-the-counter medications, and personal care items. Hypera has established a strong presence in the Brazilian market, offering a wide range of high-quality and affordable healthcare solutions. Its commitment to research and innovation has led to numerous successful product launches. Hypera SA continues to be a prominent player in the pharmaceutical industry, continuously expanding its portfolio and enhancing the well-being of consumers.
Hypera SA, a renowned company in the pharmaceutical industry, has accomplished several significant milestones throughout its journey. The company has successfully positioned itself as a leader in the Latin American market, expanding its presence across various countries. Hypera SA has consistently demonstrated its commitment to innovation and research, introducing numerous breakthrough pharmaceutical products. With strategic acquisitions and partnerships, the company has further strengthened its portfolio and market share. Hypera SA's relentless focus on quality control and strict adherence to regulatory standards has earned it a stellar reputation among industry experts and stakeholders. These achievements reflect Hypera SA's dedication to advancing healthcare solutions and driving long-term growth in the pharmaceutical sector.
Hypera SA is primarily present in Brazil.
Hypera SA represents a strong commitment to its corporate philosophy, which revolves around innovation, excellence, and integrity. With a focus on enhancing quality of life, Hypera SA aims to deliver innovative healthcare solutions to consumers. The company puts a strong emphasis on research and development, constantly striving to introduce new and effective products to market. By promoting a culture of excellence, Hypera SA seeks to provide top-notch customer service and quality-assured products. With a dedication to integrity, the company operates transparently and ethically, ensuring trust and reliability among its stakeholders. Hypera SA's values and corporate philosophy ultimately drive its mission to positively impact people's health and well-being.
Analytici aktuálně stanovují průměrnou cílovou cenu 30,54 BRL pro akcii Hypera (medián: 30,09 BRL), tedy +15,3 % vůči poslední ceně. Konsensus vychází z 19 hodnocení analytiků.
19 analytiků aktuálně hodnotí akcii Hypera: 13 doporučuje koupit, 6 držet a 0 prodat. Pro rok 2026 analytici očekávají u Hypera tržby 9,23 Mld. BRL a zisk na akcii 2,65 BRL.
Při aktuálním kurzu se akcie Hypera obchoduje za 4,68 EUR (26,49 BRL).
Akcie Hypera (HYPE3.SA) je kótována na 2 burzách, mimo jiné: B3 (São Paulo) (HYPE3.SA).
The Brazilian company Hypera SA is a leading manufacturer and distributor of pharmaceuticals, dietary supplements, cosmetics, and household products. It has been listed on the stock exchange since 2008 and has built a strong presence in the Brazilian market in recent years. Hypera SA operates in four business segments: Consumer Health, Pharma, Over-the-Counter medicines, and Cosmetics and Skincare products. The Consumer Health division offers a wide range of products such as vitamins, pain relievers, cough and cold medicines, as well as dietary supplements and baby food. Hypera SA's Pharma business includes prescription drugs, including medications for cardiovascular, diabetes, gastroenterology, and oncology patients. Additionally, the company also provides vaccines and medications for respiratory diseases. In the Over-the-Counter medicines segment, the company offers a wide range of non-prescription medications for colds, digestive issues, pain, and allergies. This includes diet and weight loss products, vitamins and minerals, as well as other supplements. Hypera SA also offers a variety of cosmetic and skincare products, including brands like Episol, Hair Fly, Monange, Neostrata, and Assolan. The company also operates a household products division, which includes brands like Vitasay, Tixan, and Blergh. The product range of Hypera SA is diverse, ranging from affordable mass-market products to more expensive premium brands. The company aims to reach a wide range of customers and has specialized in marketing products for the health and beauty segment. It has established relationships with major retail chains as well as pharmacies and other sales locations. Hypera SA strives to integrate innovation and technology into its business model. The company has a research and development team constantly developing and launching new products. It also invests in automation and digitization of its production facilities to improve the efficiency and quality of its products. Overall, Hypera SA's business model is focused on a wide product range and a strong brand presence. The company relies on price competition and innovation to strengthen its market position. As a leading provider of healthcare, cosmetic, and household products in Brazil, the company aims to expand internationally.
Tržby očekávané za Hypera činí 9,23 Mld. BRL. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Hypera činí 1,70 Mld. BRL. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Hypera je aktuálně 9,99. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Hypera.
Poměr ceny k tržbám (P/S) Hypera je aktuálně 1,85. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Hypera.
Score kvality pro Hypera je 6/10.
ISIN Hypera je BRHYPEACNOR0. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
Ticker Hypera je HYPE3.SA. Symbol tickeru se používá k obchodování akcií Hypera na burze.
Hypera akcie
Všechny fundamentální údaje o Hypera v podrobné analýze
Naše analýzy akcií společnosti Hypera zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Hypera. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: